Neurocrine Biosciences Past Earnings Performance
Past criteria checks 4/6
Neurocrine Biosciences has been growing earnings at an average annual rate of 12.2%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 21% per year. Neurocrine Biosciences's return on equity is 14.2%, and it has net margins of 17.2%.
Key information
12.2%
Earnings growth rate
10.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 21.0% |
| Return on equity | 14.2% |
| Net Margin | 17.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
Dec 18Shareholders Should Be Pleased With Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price
Dec 09
Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade)
Oct 10The Play On Neurocrine Biosciences
Oct 02Neurocrine: Buying Opportunity After Stock Price Drop On Schizophrenia Data
Aug 28Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Jul 28Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth
Jul 09Shareholders Can Be Confident That Neurocrine Biosciences' (NASDAQ:NBIX) Earnings Are High Quality
May 08Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Apr 27Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data
Apr 25Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly
Mar 31Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside
Feb 11Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings
Jan 07Revenue & Expenses Breakdown
How Neurocrine Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2,243 | 386 | 924 | 0 |
| 30 Jun 24 | 2,120 | 339 | 908 | 0 |
| 31 Mar 24 | 1,982 | 370 | 888 | 0 |
| 31 Dec 23 | 1,887 | 250 | 888 | 0 |
| 30 Sep 23 | 1,784 | 191 | 852 | 0 |
| 30 Jun 23 | 1,673 | 176 | 834 | 0 |
| 31 Mar 23 | 1,599 | 64 | 795 | 0 |
| 31 Dec 22 | 1,489 | 155 | 753 | 0 |
| 30 Sep 22 | 1,389 | 58 | 726 | 0 |
| 30 Jun 22 | 1,297 | 12 | 695 | 0 |
| 31 Mar 22 | 1,208 | 71 | 655 | 0 |
| 31 Dec 21 | 1,134 | 90 | 583 | 0 |
| 30 Sep 21 | 1,069 | 445 | 533 | 0 |
| 30 Jun 21 | 1,032 | 365 | 491 | 0 |
| 31 Mar 21 | 1,045 | 402 | 445 | 0 |
| 31 Dec 20 | 1,046 | 407 | 433 | 0 |
| 30 Sep 20 | 1,042 | 93 | 428 | 0 |
| 30 Jun 20 | 1,006 | 205 | 400 | 0 |
| 31 Mar 20 | 887 | 177 | 384 | 0 |
| 31 Dec 19 | 788 | 37 | 354 | 0 |
| 30 Sep 19 | 675 | 21 | 322 | 0 |
| 30 Jun 19 | 605 | 18 | 298 | 0 |
| 31 Mar 19 | 519 | -39 | 278 | 0 |
| 31 Dec 18 | 451 | 21 | 249 | 0 |
| 30 Sep 18 | 414 | 10 | 236 | 17 |
| 30 Jun 18 | 323 | -52 | 220 | 32 |
| 31 Mar 18 | 233 | -106 | 200 | 48 |
| 31 Dec 17 | 162 | -143 | 170 | 0 |
| 30 Sep 17 | 67 | -194 | 137 | 90 |
| 30 Jun 17 | 6 | -220 | 111 | 88 |
| 31 Mar 17 | 0 | -200 | 84 | 90 |
| 31 Dec 16 | 15 | -141 | 68 | 58 |
| 30 Sep 16 | 15 | -126 | 53 | 57 |
| 30 Jun 16 | 15 | -123 | 47 | 58 |
| 31 Mar 16 | 15 | -107 | 39 | 52 |
| 31 Dec 15 | 20 | -89 | 32 | 48 |
| 30 Sep 15 | 20 | -79 | 29 | 44 |
| 30 Jun 15 | 20 | -60 | 22 | 37 |
| 31 Mar 15 | 20 | -50 | 19 | 34 |
| 31 Dec 14 | 0 | -61 | 18 | 32 |
| 30 Sep 14 | 1 | -52 | 16 | 29 |
| 30 Jun 14 | 1 | -47 | 15 | 27 |
| 31 Mar 14 | 2 | -46 | 14 | 26 |
| 31 Dec 13 | 3 | -46 | 13 | 25 |
Quality Earnings: NBIX has a large one-off loss of $168.1M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: NBIX's current net profit margins (17.2%) are higher than last year (10.7%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NBIX's earnings have grown by 12.2% per year over the past 5 years.
Accelerating Growth: NBIX's earnings growth over the past year (102%) exceeds its 5-year average (12.2% per year).
Earnings vs Industry: NBIX earnings growth over the past year (102%) exceeded the Biotechs industry 16.6%.
Return on Equity
High ROE: NBIX's Return on Equity (14.2%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 08:12 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Neurocrine Biosciences, Inc. is covered by 50 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martha Freitag | Argus Research Company |
| Brian Skorney | Baird |
| Ishan Majumdar | Baptista Research |